ALLMedicine™ Anal Cancer Center

Jan 20th, 2022 - This exploratory study sought to characterize the anal microbiome and explore associations among the anal microbiome, risk factors for anal cancer, and clinical factors. A pilot sample of 50 HIV infected and high-risk HIV negative women were recru...

Jan 17th, 2022 - The aim of the current study was to assess temporal trends in incidence of anal squamous cell carcinomas (SCC) and high-grade anal intraepithelial lesions (AIN2/3), and estimate survival from anal cancer and factors related to 5-year mortality in ...

Jan 13th, 2022 - It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high ...

Jan 13th, 2022 - Women living with HIV (WLWH) have a greater risk of anal cancer than women without HIV; however, there are limited studies that examine awareness of anal cancer risk among WLWH and "high-risk" HIV-negative women. This study examines risk factors f...

Jan 10th, 2022 - Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify patients for treatment (de-) escala...

Jun 28th, 2021 - Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Rao S,Guren MG,Khan K,Brown G,Renehan AG,|diagnosis,epidemiology,therapy,

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

Jul 15th, 2018 - The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although certain les...

Aug 26th, 2016 - To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors. After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2...

Jul 9th, 2014 - Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2014|Glynne-Jones R,Nilsson PJ,Aschele C,Goh V,Peiffert D,|diagnosis,therapy,standards,

Jan 6th, 2022 - PRIMARY OBJECTIVE: I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. SECONDARY OBJECTIVES: I. To compar...

Oct 29th, 2021 - Background: Human papilloma virus (HPV) is one of the most common sexually transmitted diseases and a significant cause of cutaneous genital warts and anogenital cancer. Infection with high-risk, oncogenic HPV types, most commonly types 16 and 18,...

Oct 12th, 2021 - This is a single centre open label phase II trial to determine the antitumor efficacy of the oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV) -associated high grade squamous intra-epithelial lesions (HSIL) in patie...

Sep 9th, 2021 - This is a phase Ib/II clinical trial. DPX-E7 is a therapeutic vaccine, intended to treat HPV-related head and neck, cervical or anal cancer. DPX-E7 is an investigational vaccine and the FDA (the U.S. Food and Drug Administration) has not approved ...

Aug 31st, 2021 - The current project is based on the assumption that a diagnosis of human papillomavirus associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer, Oral Cavity...

Oct 15th, 2021 - OncLive® is honored to announce the 2021 Giants of the Cancer Care® inductees. The 14 winners are innovators of change whose invaluable contributions to the field have changed the trajectory of care across tumor types and improved the quality of l...

Oct 6th, 2021 - Robert I. Haddad, MD Division of Head and Neck Oncology Dana-Farber Cancer Institute Professor of medicine Harvard Medical School Boston, Massachusetts A new staging system for head and neck cancers recognizes that patients with orophar...

Oct 6th, 2021 - The constantly-evolving rectal cancer paradigm has entered an era of personalized treatment, according to Noam VanderWalde, MD, MS, who added that with the growing number of options available, a multidisciplinary team is needed to inform care deci...

Jul 26th, 2021 - In a 13 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) chose to hold off on a decision regarding accelerated approval for retifanlimab (INCMGA 0012) for the treatment of patients with locally advanced or metastatic squamous carcino...

Jun 24th, 2021 - FDA advisors told the agency to wait on more data before approving an investigational immunotherapy for squamous carcinoma of the anal canal (SCAC), largely due to questions over the drug's activity. By a 13-4 margin, the Oncologic Drugs Advisory ...